Tirzepatide 60mg

Tirzepatide 60 mg Injection represents the highest strength formulation in the Tirzepatide range, developed for patients requiring advanced glycemic and metabolic control. Offered by BLUEPILL EXPRESS, a global merchant exporter, this product is manufactured in WHO-GMP and ISO-certified facilities located in India and China depending on client requirements. The injection combines dual incretin receptor activation—GIP and GLP-1—for superior glucose regulation, enhanced insulin sensitivity, and substantial body weight reduction.
Mechanism of Action: Tirzepatide 60 mg acts as a dual GIP (Glucose-Dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptor agonist, promoting insulin release, suppressing glucagon secretion, and delaying gastric emptying. This results in reduced blood sugar, improved metabolism, and long-lasting weight management.
Therapeutic Indications: Tirzepatide 60 mg Injection is indicated for adults with Type 2 Diabetes Mellitus inadequately controlled by oral hypoglycemics or diet and exercise alone. It is also used for long-term weight management in obese and overweight individuals with metabolic complications.
Dosage and Administration: Administer Tirzepatide 60 mg once weekly via subcutaneous injection in the abdomen, thigh, or upper arm. Begin at a lower dose (2.5 mg weekly) and increase gradually under physician supervision. Do not exceed one dose per week. Maintain a consistent dosing schedule for best results.
Pharmacological Classification: Therapeutic Category – Antidiabetic / Metabolic Regulator. Drug Class – Dual GIP and GLP-1 Receptor Agonist. ATC Code – A10BJ06.
Key Features and Benefits: High-potency 60 mg strength for patients requiring enhanced metabolic effect. Dual receptor action providing comprehensive control of blood glucose and body weight. Once-weekly administration ensures convenience and compliance. Clinically proven reduction in HbA1c levels and cardiovascular risks. Flexible manufacturing availability from India and China. Meets WHO-GMP and ISO international standards. Ideal for bulk export, third-party manufacturing, and private labeling.
Precautions and Warnings: Not suitable for Type 1 Diabetes or diabetic ketoacidosis. Contraindicated in individuals with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Use cautiously in patients with pancreatitis, gastrointestinal disorders, or kidney impairment. Common side effects include nausea, vomiting, diarrhea, and decreased appetite. Avoid use during pregnancy and lactation unless specifically prescribed.
Storage and Handling: Store refrigerated between 2°C to 8°C. Do not freeze. Protect from direct sunlight and maintain cold-chain integrity during shipping and storage.
Manufacturing and Quality Compliance: BLUEPILL EXPRESS ensures Tirzepatide 60 mg Injection is produced under WHO-GMP and ISO-certified standards in India and China. Every batch undergoes rigorous testing for purity, sterility, potency, and stability. Manufacturing follows IP/BP/USP pharmacopoeial specifications to meet international export quality.
Export and Documentation Support: BLUEPILL EXPRESS provides complete export documentation including Certificate of Analysis, Certificate of Origin, Batch Manufacturing Record, Stability Report, MSDS, and Cold Chain Compliance Certificate. Full regulatory and logistics support is available for global importers.
Why Choose BLUEPILL EXPRESS: As a trusted merchant exporter, BLUEPILL EXPRESS provides flexibility of dual-country manufacturing in India and China. The company ensures strict quality control, international compliance, and reliable global shipping via air and sea. Private labeling, custom packaging, and regulatory dossier services are available.
Clinical Efficacy: Clinical data show Tirzepatide 60 mg provides significant improvements in glycemic control with up to 2.8% reduction in HbA1c and over 20% weight reduction in long-term trials. It enhances insulin sensitivity, improves lipid metabolism, and supports cardiovascular health in Type 2 Diabetes patients.
Global Distribution: BLUEPILL EXPRESS exports Tirzepatide 60 mg Injection globally including to Asia, Africa, Europe, the Middle East, and Latin America. Suitable for hospitals, distributors, and government tenders.
Conclusion: Tirzepatide 60 mg Injection is a breakthrough therapy for Type 2 Diabetes and obesity management, offering unmatched dual incretin action for comprehensive metabolic control. With manufacturing facilities in India and China and export expertise from BLUEPILL EXPRESS, clients receive premium-quality products with full compliance and global delivery reliability. BLUEPILL EXPRESS continues to lead as a trusted merchant exporter providing advanced pharmaceutical solutions worldwide.